ArticleCureus2025
The Prevalence and Trends of Contrast-Induced Nephropathy Among Hospitalized Patients Undergoing Cardiac Resynchronization Therapy.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionContrast-induced nephropathy (CIN) is a significant complication following the use of iodinated contrast agents during cardiac procedures. Cardiac resynchronization therapy (CRT), increasingly used in heart failure management, requires contrast administration, putting patients at risk for CIN. However, the prevalence and outcomes of CIN in CRT recipients remain underexplored.
methodsWe conducted a retrospective cohort study using the Nationwide Readmissions Database (NRD) from 2016 to 2020. Adult patients undergoing CRT or CRT-D implantation were identified using International Classification of Diseases, 10th edition (ICD-10) codes. The primary outcome was the annual prevalence of CIN. Secondary outcomes included 30-day hospital readmission, mortality, metabolic acidosis, hyperkalemia, and continuous renal replacement therapy (CRRT). Multivariable logistic regression assessed temporal trends, adjusting for patient demographics and comorbidities.
resultsAmong 42,545 patients undergoing CRT, CIN prevalence increased from 20.61% in 2016 to 26.40% in 2020 (p < 0.001). CIN was associated with significantly higher 30-day readmission rates, longer hospital stays (mean length of stay (LOS): 7.64 vs. 4.36 days in non-elective cases), and higher hospitalization costs. The incidence of metabolic acidosis rose from 13.73% to 18.51% (p < 0.001), and CRRT use increased from 3.30% to 5.11% (p = 0.03). While overall mortality was higher among CIN patients (2.84% vs. 0.53%), no significant trend in mortality was observed over time (p = 0.352).
conclusionCIN is an increasingly prevalent complication in patients undergoing CRT and is associated with worse clinical outcomes and higher healthcare utilization. These findings underscore the need for implementing standardized nephroprotective strategies, including contrast minimization protocols and early risk stratification, to mitigate renal complications in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.